• Jiji, Kyodo


The health ministry on Tuesday officially authorized the use of U.S. biopharmaceutical firm Novavax Inc.’s COVID-19 vaccine, making it the fourth coronavirus vaccine available in Japan.

The Novavax vaccine is a recombinant protein vaccine, unlike the three vaccines already approved. According to the ministry, the vaccine is effective against the highly infectious omicron variant of the coronavirus, albeit less so compared with other variants.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.